Article

In Silico Evaluation of Lumacaftor for Cystic Fibrosis

2024-07-24

Abstract excerpt

<title>Abstract</title> <p>Cystic fibrosis is a common life-limiting autosomal recessive genetic disorder that causes severe damage to lungs, digestive system and other organs in the body. This disease is a result of mutation in a gene that encodes for chloride-conducting transmembrane channel called CFTR, which in turn regulates mucociliary clearance and anion transport in the airways. No effective curative opti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d320539b-e8c6-56d5-b4de-2508e84ab72b
DOI: 10.21203/rs.3.rs-4773294/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

In Silico Evaluation of Lumacaftor for Cystic FibrosisDOI 10.21203/rs.3.rs-4773294/v1Read

Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.Semantic proximity Read

New and emerging targeted therapies for cystic fibrosis.Semantic proximity Read

Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.Semantic proximity Read

Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.Semantic proximity Read

Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.Semantic proximity Read

Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.Semantic proximity Read

New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.Semantic proximity Read

Advances in the Cystic Fibrosis Drug Development PipelineSemantic proximity Read

Ivacaftor for the treatment of cystic fibrosis in children under six years of age.Semantic proximity Read

The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.Semantic proximity Read

Cystic fibrosis papers of the year 2017.Semantic proximity Read

Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation.Semantic proximity Read